兰蔻产品广告遭美药监局警告

美国食品药品监督管理局日前对法国欧莱雅集团发出警告，要求其下属的兰蔻美国分公司停止在兰蔻系列护肤品广告中使用类似药品功效的描述语言。药监局表示，兰蔻系列的精华肌底修护晚霜和菁纯臻颜再生眼霜等产品广告称这些产品可以“提升基因活力”或“刺激细胞再生”以达到延缓衰老的功效。警告信指出，任何旨在对人体结构和功能产生影响的产品均应被归为药物，而未向药监局提出申请并证明其产品的安全和功效的公司是不能在美国销售这些药物的。药监局称，如果不修正上述广告词，他们将采取强制措施，比如没收产品或对生产商和销售商实行禁令等。

Regulators warned L'Oreal, the world's biggest cosmetics group, to stop advertising skincare products using language that makes them sound like drugs.

The U.S. Food and Drug Administration said Lancome USA, a L'Oreal unit, claimed some of its skin creams could "boost the activity of genes" or "stimulate cell regeneration" to reduce signs of aging.

Any product that is intended to affect the structure or function of the human body is classified as a drug, the FDA said, according to a warning letter posted on its website on Tuesday.

Companies are not allowed to sell drugs in the United States without submitting an application to the FDA proving their products are safe and effective and then winning FDA approval.

L'Oreal, a French company, was not immediately available for comment.

Some of the products mentioned in the letter, dated September 7, include Genifique Repair Youth Activating Night Cream and Absolue Eye Precious Cells Advanced Regenerating and Reconstructing Eye Cream.

On its website, Lancome describes the Genifique Repair cream, which costs $98 for a 1.7-ounce container, as "our first night care that boosts the activity of genes." The company cites an in-vitro test on genes to back up the claim.

The FDA said failure to fix the advertising claims could lead to enforcement actions, such as seizure of the products and injunctions against their manufacturers and distributors.